

79. CLAIMS

We claim:

1. A method of diagnosing an abnormality in endometrial glandular development in a woman suspected of being infertile comprising the step of:

detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from on or after day 20 of an idealized 28 day menstrual cycle from a woman suspected of being infertile;

wherein

- expression of cyclin E in the nuclei of greater than 5% of the gland cells indicates endometrial glandular developmental arrest, and/or

expression of cyclin E of greater than 1+ staining intensity in the cytoplasm of greater than 10% of the gland cells indicates endometrial glandular developmental arrest.

2. The method of claim 1 wherein the expression of cyclin E is detected by an immunohistochemistry assay.

3. The method of claim 1 wherein the cycle day is determined by examining the stroma cells in the sample.

4. The method of claim 1 wherein expression of cyclin E is detected in the nuclei of greater than 10% of the gland cells in the sample is indicative of endometrial glandular developmental arrest.

5. The method of claim 1 wherein the cycle day is day 24 of an idealized 28 day menstrual cycle.

6. The method of claim 1 further comprising the step of detecting the expression of p27 in the nuclei of gland cells in a serial section of the sample.

30

7. The method of claim 1 further comprising the step of detecting the expression of progesterone receptor in the gland cells in a serial section of the sample.

8. The method of claim 1 further comprising the step of detecting the expression of mouse ascites golgi mucin MAG in the gland cells in a serial section of the sample.

9. The method of claim 1 further comprising the steps of detecting the expression of p27 in the nuclei of gland cells in a serial section of the sample and either detecting the expression of progesterone receptor in the gland cells in a serial section of the sample or detecting the expression of MAG in the gland cells in a serial section of the sample or both.

10. The method of claim 1 further comprising the step of detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

11. The method of claim 1 further comprising the step of detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from day 15 an idealized 28 day menstrual cycle from the woman.

12. The method of claim 1 further comprising the step of detecting expression of p27 in the nuclei of endometrial gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

13. The method of claim 1 further comprising the step of detecting expression of p27 in the nuclei of endometrial gland cells in an endometrial tissue sample from before day 17 of an idealized 28 day menstrual cycle from the woman wherein expression of p27 is indicative of accelerated endometrial glandular development.

14. The method of claim 1 further comprising the step of detecting expression of progesterone receptor in the gland cells in an endometrial tissue sample from before day 18 of an idealized 28 day menstrual cycle from the woman.

5 15. The method of claim 1 further comprising the step of detecting the expression of MAG in the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

10 16. The method of claim 1 further comprising at least two of the following steps of:
a) detecting the expression of cyclin E in the nuclei and/or cytoplasm of the gland cells in an endometrial tissue sample from on or before day 18 of a an idealized 28 day menstrual cycle from the woman;
15 b) detecting the expression of p27 in the nuclei of gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
c) detecting expression of progesterone receptor in gland cells in an endometrial tissue sample on or before day 18 of an idealized 28 day menstrual cycle from the woman;
20 d) detecting the expression of MAG in the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
wherein said two or more steps are performed on serial sections of the sample.

25 17. A method of predicting abnormal endometrial glandular development comprising the steps of :
detecting the level of p27 in the nuclei of cells in a sample of endometrial tissue from day 10-18 of a an idealized 28 day menstrual cycle from a woman suspected of being infertile, and
comparing the level of expression with an expected level of expression;
wherein detection of elevated levels of p27 in the sample is predictive that the
30 woman will be diagnosed with endometrial glandular developmental arrest.

18. The method of claim 17 wherein the expression of p27 is detected by an immunohistochemistry assay.

19. The method of claim 17 wherein the cycle day is determined by examining the stroma and gland cells in the sample.

20. The method of claim 17 wherein the cycle day is day 15 of an idealized 28 day menstrual cycle.

21. The method of claim 17 further comprising the step of detecting the expression of cyclin E in the nuclei and /or cytoplasm of gland cells in a serial section of the sample.

22. The method of claim 17 further comprising the step of detecting the expression of progesterone receptor in the gland cells in a serial section of the sample.

23. The method of claim 17 further comprising the step of detecting the expression of MAG in the gland cells in a serial section of the sample.

24. The method of claim 17 further comprising at least two of the following steps of:

- a) detecting the expression of cyclin E in the nuclei and/or cytoplasm of the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
- b) detecting expression of progesterone receptor in gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
- c) detecting the expression of MAG in the gland cells in an endometrial tissue sample on or before day 18 of an idealized 28 day menstrual cycle from the woman;

wherein said two or more steps are performed on serial sections of the sample.

25. A method of assessing the suitability of the endometrium for embryo implantation in a woman undergoing ovulation induction comprising the step of:

09301470-030801

detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from before day 17 of an idealized 28 day menstrual cycle;

wherein

5 expression of cyclin E in the nuclei of greater than 5% of the gland cells indicates the endometrium is unsuitable for embryo implantation; and/or

expression of cyclin E of 2-3+ staining intensity in the cytoplasm of less than 50% of the gland cells indicates the endometrium is unsuitable for embryo implantation.

10 26. The method of claim 25 wherein the expression of cyclin E is detected by an immunohistochemistry assay.

27. The method of claim 25 wherein the cycle day is determined by examining the stroma and gland cells in the sample.

15 28. The method of claim 25 wherein expression of cyclin E is detected in the nuclei of greater than 10% of the gland cells in the sample indicates the endometrium is unsuitable for embryo implantation.

20 29. The method of claim 25 wherein the cycle day is day 15 of an idealized 28 day menstrual cycle.

30. The method of claim 25 further comprising the step of detecting the expression of p27 in the nuclei of gland cells in a serial section of the sample wherein detection of
25 expression of p27 in the nuclei of greater than 0% of the gland cells in the sample indicates the endometrium is unsuitable for embryo implantation.

31. The method of claim 25 further comprising the step of detecting the expression of p27 in the nuclei of gland cells in a serial section of the sample wherein detection of
30 expression of p27 in the nuclei of greater than 5% of the gland cells in the sample indicates the endometrium is unsuitable for embryo implantation.

of claim 25 further comprising the s
or in less than 10% of the gland cells

of claim 25 further comprising the
cells in a serial section of the sample
10% of the gland cells in the sam
to implantation.

of claim 25 further comprising the s
gland cells in a serial section of th
sterone receptor in the gland cells in
sion of MAG in the gland cells in

of claim 25 further comprising at lea
expression of p27 in the nuclei of gl
pression of progesterone receptor
e;
e expression of MAG in the glan

more steps are performed on serial s

of claim 25 wherein the woman is
ure selected from the group c
IUI following clomiphene hyp
d GIFT following hyperstimulation.

5

10

15

wherein said two or more steps are performed on serial sections of the sample.

1. 1990-1991		2. 1991-1992		3. 1992-1993		4. 1993-1994		5. 1994-1995		6. 1995-1996		7. 1996-1997		8. 1997-1998		9. 1998-1999		10. 1999-2000		11. 2000-2001		12. 2001-2002		13. 2002-2003		14. 2003-2004		15. 2004-2005		16. 2005-2006		17. 2006-2007		18. 2007-2008		19. 2008-2009		20. 2009-2010		21. 2010-2011		22. 2011-2012		23. 2012-2013		24. 2013-2014		25. 2014-2015		26. 2015-2016		27. 2016-2017		28. 2017-2018		29. 2018-2019		30. 2019-2020		31. 2020-2021		32. 2021-2022		33. 2022-2023		34. 2023-2024		35. 2024-2025		36. 2025-2026		37. 2026-2027		38. 2027-2028		39. 2028-2029		40. 2029-2030		41. 2030-2031		42. 2031-2032		43. 2032-2033		44. 2033-2034		45. 2034-2035		46. 2035-2036		47. 2036-2037		48. 2037-2038		49. 2038-2039		50. 2039-2040		51. 2040-2041		52. 2041-2042		53. 2042-2043		54. 2043-2044		55. 2044-2045		56. 2045-2046		57. 2046-2047		58. 2047-2048		59. 2048-2049		60. 2049-2050		61. 2050-2051		62. 2051-2052		63. 2052-2053		64. 2053-2054		65. 2054-2055		66. 2055-2056		67. 2056-2057		68. 2057-2058		69. 2058-2059		70. 2059-2060		71. 2060-2061		72. 2061-2062		73. 2062-2063		74. 2063-2064		75. 2064-2065		76. 2065-2066		77. 2066-2067		78. 2067-2068		79. 2068-2069		80. 2069-2070		81. 2070-2071		82. 2071-2072		83. 2072-2073		84. 2073-2074		85. 2074-2075		86. 2075-2076		87. 2076-2077		88. 2077-2078		89. 2078-2079		90. 2079-2080		91. 2080-2081		92. 2081-2082		93. 2082-2083		94. 2083-2084		95. 2084-2085		96. 2085-2086		97. 2086-2087		98. 2087-2088		99. 2088-2089		100. 2089-2090		101. 2090-2091		102. 2091-2092		103. 2092-2093		104. 2093-2094		105. 2094-2095		106. 2095-2096		107. 2096-2097		108. 2097-2098		109. 2098-2099		110. 2099-2100		111. 2100-2101		112. 2101-2102		113. 2102-2103		114. 2103-2104		115. 2104-2105		116. 2105-2106		117. 2106-2107		118. 2107-2108		119. 2108-2109		120. 2109-2110		121. 2110-2111		122. 2111-2112		123. 2112-2113		124. 2113-2114		125. 2114-2115		126. 2115-2116		127. 2116-2117		128. 2117-2118		129. 2118-2119		130. 2119-2120		131. 2120-2121		132. 2121-2122		133. 2122-2123		134. 2123-2124		135. 2124-2125		136. 2125-2126		137. 2126-2127		138. 2127-2128		139. 2128-2129		140. 2129-2130		141. 2130-2131		142. 2131-2132		143. 2132-2133		144. 2133-2134		145. 2134-2135		146. 2135-2136		147. 2136-2137		148. 2137-2138		149. 2138-2139		150. 2139-2140		151. 2140-2141		152. 2141-2142		153. 2142-2143		154. 2143-2144		155. 2144-2145		156. 2145-2146		157. 2146-2147		158. 2147-2148		159. 2148-2149		160. 2149-2150		161. 2150-2151		162. 2151-2152		163. 2152-2153		164. 2153-2154		165. 2154-2155		166. 2155-2156		167. 2156-2157		168. 2157-2158		169. 2158-2159		170. 2159-2160		171. 2160-2161		172. 2161-2162		173. 2162-2163		174. 2163-2164		175. 2164-2165		176. 2165-2166		177. 2166-2167		178. 2167-2168		179. 2168-2169		180. 2169-2170		181. 2170-2171		182. 2171-2172		1	
--------------	--	--------------	--	--------------	--	--------------	--	--------------	--	--------------	--	--------------	--	--------------	--	--------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	---------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	----------------	--	---	--

detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from on or after day 20 of an idealized 28 day menstrual cycle from a woman undergoing a hormonal protocol to produce a mock cycle; and

5 wherein

expression of cyclin E in the nuclei of greater than 5% of the gland cells indicates endometrial glandular developmental arrest, and/or

expression of cyclin E of greater than 1+ staining intensity in the cytoplasm of greater than 10% of the gland cells indicates endometrial glandular developmental arrest.

10

38. The method of claim 37 wherein the expression of cyclin E is detected by an immunohistochemistry assay.

15

39. The method of claim 37 wherein expression of cyclin E is detected in the nuclei of greater than 10% of the gland cells in the sample is indicative of endometrial glandular developmental arrest.

20

40. The method of claim 37 wherein the cycle day is day 24 of an idealized 28 day menstrual cycle.

25

41. The method of claim 37 further comprising the step of detecting the expression of p27 in the nuclei of gland cells in a serial section of the sample.

30

42. The method of claim 37 further comprising the step of detecting the expression of progesterone receptor in the gland cells in a serial section of the sample.

43. The method of claim 37 further comprising the step of detecting the expression of MAG in the gland cells in a serial section of the sample.

35

44. The method of claim 37 further comprising the steps of detecting the expression of p27 in the nuclei of gland cells in a serial section of the sample and either detecting the

expression of progesterone receptor in the gland cells in a serial section of the sample or detecting the expression of MAG in the gland cells in a serial section of the sample or both.

5 45. The method of claim 37 further comprising the step of detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

10 46. The method of claim 37 further comprising the step of detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from day 15 of an idealized 28 day menstrual cycle from the woman.

15 47. The method of claim 37 further comprising the step of detecting expression of p27 in the nuclei of endometrial gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

20 48. The method of claim 37 further comprising the step of detecting expression of p27 in the nuclei of endometrial gland cells in an endometrial tissue sample from before day 17 of an idealized 28 day menstrual cycle from the woman wherein expression of p27 of greater than 0% is indicative of accelerated endometrial glandular development.

25 49. The method of claim 37 further comprising the step of detecting expression of progesterone receptor in the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

30 50. The method of claim 37 further comprising the step of detecting the expression of MAG in the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman.

51. The method of claim 36 further comprising at least two of the following steps of:

- 5 a) detecting the expression of cyclin E in the nuclei and/or cytoplasm of the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
- b) detecting the expression of p27 in the nuclei of gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
- 10 c) detecting expression of progesterone receptor in gland cells in an endometrial tissue sample on or before day 18 of an idealized 28 day menstrual cycle from the woman;
- d) detecting the expression of MAG in the gland cells in an endometrial tissue sample from on or before day 18 of an idealized 28 day menstrual cycle from the woman;
- wherein said two or more steps are performed on serial sections of the sample.

15 52. The method of claim 37 further comprising the step of adjusting the hormonal protocol following evaluation.

53. The method of claim 52 further comprising the step of repeating the evaluation method in a second mock trial following the adjusting of the hormonal protocol.

20 54. A method of evaluating a hormone replacement therapy protocol in a woman undergoing hormone replacement therapy, said method comprising the steps of :

detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from said woman;

25 detecting expression of p27 in the nuclei an of endometrial gland cells in serial section of said endometrial tissue sample;

wherein

expression of cyclin E in the nuclei of greater than 5% of the gland cells indicates excessive estrogen, and/or

30 expression of cyclin E of greater than 1+ staining intensity in the cytoplasm of greater than 10% of the gland cells indicates excessive estrogen; and/or

expression of p27 in the nuclei of less than 20% of the gland cells indicates deficient progesterone.

55. The method of claim 54 wherein the expression of cyclin E and p27 is detected by an immunohistochemistry assay.

56. The method of claim 54 further comprising the step of detecting the expression of progesterone receptor in the gland cells in a serial section of the sample.

57. The method of claim 54 further comprising the step of detecting the expression of MAG in the gland cells in a serial section of the sample wherein expression of MAG in greater than 10% of the gland cells indicates excessive estrogen or insufficient progesterone.

58. The method of claim 54 further comprising the steps of detecting the expression of progesterone receptor in the gland cells in a serial section of the sample and detecting the expression of MAG in the gland cells in a serial section of the sample.

59. The method of claim 54 further comprising the step of adjusting the hormonal protocol following evaluation.

60. The method of claim 59 further comprising the step of repeating the evaluation method following the adjusting of the hormonal protocol.

61. A method of diagnosing endometrial glandular mitotic arrest in a woman suspected of having endometrial hyperplasia comprising the step of:

detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from said woman;

detecting expression of p27 in the nuclei of endometrial gland cells in serial section of said endometrial tissue sample;

wherein

expression of cyclin E in the nuclei of less than 10% of the gland cells and expression of p27 in the nuclei of greater than 10% of the gland cells indicates endometrial glandular mitotic arrest.

5 62. The method of claim 61 wherein the expression of cyclin E and p27 is detected by an immunohistochemistry assay.

63. The method of claim 62 wherein a histological evaluation indicates possible hyperplasia.

ADD
A2

ADD
B5

FORWARDED BY 0301470 03001